American Journal of Cardiovascular Drugs

, Volume 16, Issue 3, pp 201–219 | Cite as

Efficacy of Short-Term Statin Treatment for the Prevention of Contrast-Induced Acute Kidney Injury in Patients Undergoing Coronary Angiography/Percutaneous Coronary Intervention: A Meta-Analysis of 21 Randomized Controlled Trials

  • Haixia Li
  • Cailian Wang
  • Chuanzhi Liu
  • Ruifei Li
  • Meijuan Zou
  • Gang ChengEmail author
Systematic Review



The results of previous studies have been contradictory in terms of the efficacy of statin treatment in preventing contrast-induced acute kidney injury (CI-AKI) and clinical adverse events (AEs).


This meta-analysis was undertaken to assess the role of short-term statin treatment in the prevention of CI-AKI and clinical AEs.


We searched the Cochrane Library, EMBASE, and PubMed databases for randomized controlled trials (RCTs) with the development of CI-AKI as a primary outcome. Secondary outcomes were the post-procedural serum creatinine (SCr) level, estimated glomerular filtration rate (eGFR), and development of AEs. We also performed prespecified subgroup analyses.


A total of 21 RCTs involving 7746 patients were included. Short-term statin treatment significantly reduced the risk of CI-AKI [risk ratio (RR) 0.57; 95 % confident interval (CI) 0.47–0.69; p < 0.00001) and was associated with a lower post-procedural SCr level and a higher eGFR. High-dose statins resulted in a lower incidence of CI-AKI than the lower-dose statins. In addition, the benefit was seen across various subgroups for patients at risk of CI-AKI, statin-naïve patients, and East Asians, regardless of statin type, definition of CI-AKI, use of N-acetylcysteine (NAC) and hydration, and osmolality of contrast. However, there was no significant difference between the two groups in terms of the incidence of AEs.


The meta-analysis suggests that short-term statin treatment can effectively prevent CI-AKI, and the benefit is also observed in high-risk patients, statin-naïve patients, and an East Asian population. However, the effect of simvastatin for the prevention of CI-AKI, of statins for the prevention of AEs, and whether high-dose statins have a better effect than lower-dose statins are all still uncertain.


Chronic Kidney Disease Statin Percutaneous Coronary Intervention Simvastatin Atorvastatin 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



The authors gratefully acknowledge Dr. David Jack for his assistance with language editing.

Compliance with Ethical Standards


No sources of funding were used to assist in the preparation of this study.

Conflicts of interest

Haixia Li, Cailian Wang, Chuanzhi Liu, Ruifei Li, Meijuan Zou, and Gang Cheng have no conflicts of interest that might be relevant to the contents of this study.

Supplementary material

40256_2016_164_MOESM1_ESM.pdf (135 kb)
Supplementary material 1 (PDF 136 kb)
40256_2016_164_MOESM2_ESM.pdf (184 kb)
Supplementary material 2 (PDF 184 kb)
40256_2016_164_MOESM3_ESM.pdf (169 kb)
Supplementary material 3 (PDF 169 kb)
40256_2016_164_MOESM4_ESM.pdf (173 kb)
Supplementary material 4 (PDF 173 kb)
40256_2016_164_MOESM5_ESM.pdf (160 kb)
Supplementary material 5 (PDF 161 kb)
40256_2016_164_MOESM6_ESM.pdf (166 kb)
Supplementary material 6 (PDF 166 kb)
40256_2016_164_MOESM7_ESM.pdf (106 kb)
Supplementary material 7 (PDF 107 kb)
40256_2016_164_MOESM8_ESM.pdf (105 kb)
Supplementary material 8 (PDF 105 kb)
40256_2016_164_MOESM9_ESM.pdf (87 kb)
Supplementary material 9 (PDF 87 kb)
40256_2016_164_MOESM10_ESM.pdf (113 kb)
Supplementary material 10 (PDF 114 kb)
40256_2016_164_MOESM11_ESM.pdf (107 kb)
Supplementary material 11 (PDF 108 kb)
40256_2016_164_MOESM12_ESM.pdf (184 kb)
Supplementary material 12 (PDF 185 kb)


  1. 1.
    Dangas G, Iakovou I, Nikolsky E, Aymong ED, Mintz GS, Kipshidze NN, et al. Contrast-induced nephropathy after percutaneous coronary interventions in relation to chronic kidney disease and hemodynamic variables. Am J Cardiol. 2005;95(1):13–9.CrossRefPubMedGoogle Scholar
  2. 2.
    McCullough PA, Wolyn R, Rocher LL, Levin RN, O’Neill WW. Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality. Am J Med. 1997;103(5):368–75.CrossRefPubMedGoogle Scholar
  3. 3.
    Nash K, Hafeez A, Hou S. Hospital-acquired renal insufficiency. Am J Kidney Dis. 2002;39(5):930–6.CrossRefPubMedGoogle Scholar
  4. 4.
    Lloyd-Jones D, Adams RJ, Brown TM, Carnethon M, Dai S, De Simone G, et al. Heart disease and stroke statistics—2010 update: a report from American Heart Association. Circulation. 2010;121(7):e46–215.CrossRefPubMedGoogle Scholar
  5. 5.
    Owen RJ, Hiremath S, Myers A, Fraser-Hill M, Barrett BJ. Canadian Association of Radiologists consensus guidelines for the prevention of contrast-induced nephropathy: update 2012. Can Assoc Radiol J. 2014;65(2):96–105.CrossRefPubMedGoogle Scholar
  6. 6.
    Schilp J, de Blok C, Langelaan M, Spreeuwenberg P, Wagner C. Guideline adherence for identification and hydration of high-risk hospital patients for contrast-induced nephropathy. BMC Nephrol. 2014;15:2.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Levy EM, Viscoli CM, Horwitz RI. The effect of acute renal failure on mortality. A cohort analysis. JAMA. 1996;275(19):1489–94.PubMedGoogle Scholar
  8. 8.
    Subramanian S, Tumlin J, Bapat B, Zyczynski T. Economic burden of contrast-induced nephropathy: implications for prevention strategies. J Med Econ. 2007;10(2):119–34.CrossRefPubMedGoogle Scholar
  9. 9.
    Weisbord SD, Palevsky PM. Contrast-induced acute kidney injury: short- and long-term implications. Semin Nephrol. 2011;31(3):300–9.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Morcos SK, Thomsen HS, Webb JA. Contrast-media-induced nephrotoxicity: a consensus report. Contrast Media Safety Committee, European Society of Urogenital Radiology (ESUR). Eur Radiol. 1999;9(8):1602–13.CrossRefPubMedGoogle Scholar
  11. 11.
    Bartholomew BA, Harjai KJ, Dukkipati S, Boura JA, Yerkey MW, Glazier S, et al. Impact of nephropathy after percutaneous coronary intervention and a method for risk stratification. Am J Cardiol. 2004;93(12):1515–9.CrossRefPubMedGoogle Scholar
  12. 12.
    Bagshaw SM, McAlister FA, Manns BJ, Ghali WA. Acetylcysteine in the prevention of contrast-induced nephropathy: a case study of the pitfalls in the evolution of evidence. Arch Intern Med. 2006;166(2):161–6.CrossRefPubMedGoogle Scholar
  13. 13.
    Gonzales DA, Norsworthy KJ, Kern SJ, Banks S, Sieving PC, Star RA, et al. A meta-analysis of N-acetylcysteine in contrast-induced nephrotoxicity: unsupervised clustering to resolve heterogeneity. BMC Med. 2007;5:32.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Marzilli M. Pleiotropic effects of statins: evidence for benefits beyond LDL-cholesterol lowering. Am J Cardiovasc Drugs. 2010;10(suppl 1):3–9.CrossRefPubMedGoogle Scholar
  15. 15.
    Cao S, Wang P, Cui K, Zhang L, Hou Y. Atorvastatin prevents contrast agent-induced renal injury in patients undergoing coronary angiography by inhibiting oxidative stress. Nan Fang Yi Ke Da Xue Xue Bao. 2012;32(11):1600–2.PubMedGoogle Scholar
  16. 16.
    Han Y, Zhu G, Han L, Hou F, Huang W, Liu H, et al. Short-term rosuvastatin therapy for prevention of contrast-induced acute kidney injury in patients with diabetes and chronic kidney disease. J Am Coll Cardiol. 2014;63(1):62–70.CrossRefPubMedGoogle Scholar
  17. 17.
    Xinwei J, Xianghua F, Jing Z, Xinshun G, Ling X, Weize F, et al. Comparison of usefulness of simvastatin 20 mg versus 80 mg in preventing contrast-induced nephropathy in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Am J Cardiol. 2009;104(4):519–24.CrossRefPubMedGoogle Scholar
  18. 18.
    Leoncini M, Toso A, Maioli M, Tropeano F, Villani S, Bellandi F. Early high-dose rosuvastatin for contrast-induced nephropathy prevention in acute coronary syndrome: Results from the PRATO-ACS Study (Protective Effect of Rosuvastatin and Antiplatelet Therapy On contrast-induced acute kidney injury and myocardial damage in patients with Acute Coronary Syndrome). J Am Coll Cardiol. 2014;63(1):71–9.CrossRefPubMedGoogle Scholar
  19. 19.
    Li W, Fu X, Wang Y, Li X, Yang Z, Wang X, et al. Beneficial effects of high-dose atorvastatin pretreatment on renal function in patients with acute ST-segment elevation myocardial infarction undergoing emergency percutaneous coronary intervention. Cardiology. 2012;122(3):195–202.CrossRefPubMedGoogle Scholar
  20. 20.
    Patti G, Ricottini E, Nusca A, Colonna G, Pasceri V, D’Ambrosio A, et al. Short-term, high-dose atorvastatin pretreatment to prevent contrast-induced nephropathy in patients with acute coronary syndromes undergoing percutaneous coronary intervention (from the ARMYDA-CIN [atorvastatin for reduction of myocardial damage during angioplasty–contrast-induced nephropathy] trial. Am J Cardiol. 2011;108(1):1–7.CrossRefPubMedGoogle Scholar
  21. 21.
    Yun KH, Lim JH, Hwang KB, Woo SH, Jeong JW, Kim YC, et al. Effect of high dose rosuvastatin loading before percutaneous coronary intervention on contrast-induced nephropathy. Korean Circ J. 2014;44(5):301–6.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Abaci O, Arat Ozkan A, Kocas C, Cetinkal G, Sukru Karaca O, Baydar O, et al. Impact of rosuvastatin on contrast-induced acute kidney injury in patients at high risk for nephropathy undergoing elective angiography. Am J Cardiol. 2015;115(7):867–71.CrossRefPubMedGoogle Scholar
  23. 23.
    de Oliveira MS, Martins KBA, Costa JR Jr, Abizaid A, Stadler J, Mattos LA, et al. Impact on renal function of rosuvastatin preload prior to elective percutaneous coronary intervention in chronic statin users. Rev Bras Cardiol Invasiva. 2012;20:303–8.Google Scholar
  24. 24.
    Han S, Li XM, Mohammed Ali LA, Fu NK, Jin DX, Cong HL. Effect of short-term different statins loading dose on renal function and CI-AKI incidence in patients undergoing invasive coronary procedures. Int J Cardiol. 2013;168(5):5101–3.CrossRefPubMedGoogle Scholar
  25. 25.
    Jo SH, Koo BK, Park JS, Kang HJ, Cho YS, Kim YJ, et al. Prevention of radiocontrast medium-induced nephropathy using short-term high-dose simvastatin in patients with renal insufficiency undergoing coronary angiography (PROMISS) trial—a randomized controlled study. Am Heart J. 2008;155(3):499.e1–8.Google Scholar
  26. 26.
    Ozhan H, Erden I, Ordu S, Aydin M, Caglar O, Basar C, et al. Efficacy of short-term high-dose atorvastatin for prevention of contrast-induced nephropathy in patients undergoing coronary angiography. Angiology. 2010;61(7):711–4.CrossRefPubMedGoogle Scholar
  27. 27.
    Qiao B, Deng J, Li Y, Wang X, Han Y. Rosuvastatin attenuated contrast-induced nephropathy in diabetes patients with renal dysfunction. Int J Clin Exp Med. 2015;8(2):2342–9.PubMedPubMedCentralGoogle Scholar
  28. 28.
    Quintavalle C, Fiore D, De Micco F, Visconti G, Focaccio A, Golia B, et al. Impact of a high loading dose of atorvastatin on contrast-induced acute kidney injury. Circulation. 2012;126(25):3008–16.CrossRefPubMedGoogle Scholar
  29. 29.
    Sanei H, Hajian-Nejad A, Sajjadieh-Kajouei A, Nazemzadeh N, Alizadeh N, Bidram P, et al. Short term high dose atorvastatin for the prevention of contrast-induced nephropathy in patients undergoing computed tomography angiography. ARYA Atheroscler. 2014;10(5):252–8.PubMedPubMedCentralGoogle Scholar
  30. 30.
    Shehata M, Hamza M. Impact of high loading dose of atorvastatin in diabetic patients with renal dysfunction undergoing elective percutaneous coronary intervention: a randomized controlled trial. Cardiovasc Ther. 2015;33(2):35–41.CrossRefPubMedGoogle Scholar
  31. 31.
    Toso A, Maioli M, Leoncini M, Gallopin M, Tedeschi D, Micheletti C, et al. Usefulness of atorvastatin (80 mg) in prevention of contrast-induced nephropathy in patients with chronic renal disease. Am J Cardiol. 2010;105(3):288–92.CrossRefPubMedGoogle Scholar
  32. 32.
    Zhou X, Jin YZ, Wang Q, Min R, Zhang XY. Efficacy of high dose atorvastatin on preventing contrast induced nephropathy in patients underwent coronary angiography. Zhonghua Xin Xue Guan Bing Za Zhi. 2009;37(5):394–6.PubMedGoogle Scholar
  33. 33.
    Zhou Y, Yuan WJ, Zhu N, Wang L. Short-term, high-dose statins in the prevention of contrast-induced nephropathy: a systematic review and meta-analysis. Clin Nephrol. 2011;76(6):475–83.CrossRefPubMedGoogle Scholar
  34. 34.
    Zhang L, Zhang L, Lu Y, Wu B, Zhang S, Jiang H, et al. Efficacy of statin pretreatment for the prevention of contrast-induced nephropathy: a meta-analysis of randomised controlled trials. Int J Clin Pract. 2011;65(5):624–30.CrossRefPubMedGoogle Scholar
  35. 35.
    Zhang T, Shen LH, Hu LH, He B. Statins for the prevention of contrast-induced nephropathy: a systematic review and meta-analysis. Am J Nephrol. 2011;33(4):344–51.CrossRefPubMedGoogle Scholar
  36. 36.
    Pappy R, Stavrakis S, Hennebry TA, Abu-Fadel MS. Effect of statin therapy on contrast-induced nephropathy after coronary angiography: a meta-analysis. Int J Cardiol. 2011;151(3):348–53.CrossRefPubMedGoogle Scholar
  37. 37.
    Li Y, Liu Y, Fu L, Mei C, Dai B. Efficacy of short-term high-dose statin in preventing contrast-induced nephropathy: a meta-analysis of seven randomized controlled trials. PLoS One. 2012;7(4):e34450.CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Singh N, Lee JZ, Huang JJ, Low SW, Howe C, Pandit A, et al. Benefit of statin pretreatment in prevention of contrast-induced nephropathy in different adult patient population: systematic review and meta-analysis. Open Heart. 2014;1(1):e000127.CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Moher D, Liberati A, Tetzlaff J, Altman DG. PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535.CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions version 5.1.0 [updated March 2011]. The Cochrane Collaboration; 2011. Accessed 23 Aug 2015.
  41. 41.
    Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol. 2011;64(4):383–94.CrossRefPubMedGoogle Scholar
  42. 42.
    Riley RD, Higgins JP, Deeks JJ. Interpretation of random effects meta-analyses. BMJ. 2011;342:d549.CrossRefPubMedGoogle Scholar
  43. 43.
    Acikel S, Muderrisoglu H, Yildirir A, Aydinalp A, Sade E, Bayraktar N, et al. Prevention of contrast-induced impairment of renal function by short-term or long-term statin therapy in patients undergoing elective coronary angiography. Blood Coagul Fibrinolysis. 2010;21(8):750–7.PubMedGoogle Scholar
  44. 44.
    Chen GL, Su JZ. Atorvastatin attenuated contrast induced renal function damage. Zhonghua Xin Xue Guan Bing Za Zhi. 2009;37(5):389–93.PubMedGoogle Scholar
  45. 45.
    Sanadgol H, Abdani S, Tabatabaiee P, Mohammadi M. Protective effect of high dose short term statin therapy with normal saline in prevention of contrast-induced nephropathy among iodixanol-receiving patients. J Renal Inj Prev. 2012;1(1):43–5.PubMedPubMedCentralGoogle Scholar
  46. 46.
    Liss P, Nygren A, Olsson U, Ulfendahl HR, Erikson U. Effects of contrast media and mannitol on renal medullary blood flow and red cell aggregation in the rat kidney. Kidney Int. 1996;49(5):1268–75.CrossRefPubMedGoogle Scholar
  47. 47.
    Liss P. Effects of contrast media on renal microcirculation and oxygen tension. An experimental study in the rat. Acta Radiol Suppl. 1997;409:1–29.PubMedGoogle Scholar
  48. 48.
    Liss P, Nygren A, Hansell P. Hypoperfusion in the renal outer medulla after injection of contrast media in rats. Acta Radiol. 1999;40(5):521–7.CrossRefPubMedGoogle Scholar
  49. 49.
    Sendeski M, Patzak A, Pallone TL, Cao C, Persson AE, Persson PB. Iodixanol, constriction of medullary descending vasa recta, and risk for contrast medium-induced nephropathy. Radiology. 2009;251(3):697–704.CrossRefPubMedPubMedCentralGoogle Scholar
  50. 50.
    Clark BA, Kim D, Epstein FH. Endothelin and atrial natriuretic peptide levels following radiocontrast exposure in humans. Am J Kidney Dis. 1997;30(1):82–6.CrossRefPubMedGoogle Scholar
  51. 51.
    Andreucci M, Lucisano G, Faga T, Bertucci B, Tamburrini O, Pisani A, et al. Differential activation of signaling pathways involved in cell death, survival and inflammation by radiocontrast media in human renal proximal tubular cells. Toxicol Sci. 2011;119(2):408–16.CrossRefPubMedGoogle Scholar
  52. 52.
    Caiazza A, Russo L, Sabbatini M, Russo D. Hemodynamic and tubular changes induced by contrast media. Biomed Res Int. 2014;2014:578974.CrossRefPubMedPubMedCentralGoogle Scholar
  53. 53.
    Heyman SN, Rosen S, Khamaisi M, Idée JM, Rosenberger C. Reactive oxygen species and the pathogenesis of radiocontrast-induced nephropathy. Invest Radiol. 2010;45(4):188–95.CrossRefPubMedGoogle Scholar
  54. 54.
    Katholi RE, Woods WT Jr, Taylor GJ, Deitrick CL, Womack KA, Katholi CR, et al. Oxygen free radicals and contrast nephropathy. Am J Kidney Dis. 1998;32(1):64–71.CrossRefPubMedGoogle Scholar
  55. 55.
    Walter DH, Dimmeler S, Zeiher AM. Effects of statins on endothelium and endothelial progenitor cell recruitment. Semin Vasc Med. 2004;4(4):385–93.CrossRefPubMedGoogle Scholar
  56. 56.
    Ridker PM, Rifai N, Clearfield M, Downs JR, Weis SE, Miles JS, et al. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med. 2001;344(26):1959–65.CrossRefPubMedGoogle Scholar
  57. 57.
    Liu YH, Liu Y, Duan CY, Tan N, Chen JY, Zhou YL, et al. Statins for the prevention of contrast-induced nephropathy after coronary angiography/percutaneous interventions: a meta-analysis of randomized controlled trials. J Cardiovasc Pharmacol Ther. 2015;20(2):181–92.CrossRefPubMedGoogle Scholar
  58. 58.
    Cheungpasitporn W, Thongprayoon C, Kittanamongkolchai W, Edmonds PJ, O’Corragain OA, Srivali N, et al. Periprocedural effects of statins on the incidence of contrast-induced acute kidney injury: a systematic review and meta-analysis of randomized controlled trials. Ren Fail. 2015;37(4):664–71.CrossRefPubMedGoogle Scholar
  59. 59.
    Marenzi G, Cosentino N, Werba JP, Tedesco CC, Veglia F, Bartorelli AL. A meta-analysis of randomized controlled trials on statins for the prevention of contrast-induced acute kidney injury in patients with and without acute coronary syndromes. Int J Cardiol. 2015;183:47–53.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2016

Authors and Affiliations

  • Haixia Li
    • 1
  • Cailian Wang
    • 2
  • Chuanzhi Liu
    • 3
  • Ruifei Li
    • 1
  • Meijuan Zou
    • 1
  • Gang Cheng
    • 1
    Email author
  1. 1.Shenyang Pharmaceutical UniversityShenyangChina
  2. 2.Department of CardiologyGeneral Hospital of Shenyang Military AreaShenyangChina
  3. 3.Department of NephrologyGeneral Hospital of Shenyang Military AreaShenyangChina

Personalised recommendations